IDYA / IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates

IDEAYA Biosciences specializes in precision oncology, has FDA clearance for a Phase 1/2 trial, and partnerships with Amgen and GSK. Financially stable more_horizontal

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compare more_horizontal

Today, we take our first in-depth look at a developmental concerned called Ideaya Biosciences, Inc. Ideaya Biosciences is moving forward a diverse pip more_horizontal

Fintel reports that on May 24, 2023, Goldman Sachs initiated coverage of Ideaya Biosciences (NASDAQ:IDYA) with a Buy recommendation. more_horizontal

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compare more_horizontal

IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate re more_horizontal

IDEAYA Biosciences shares jumped after the company posted additional positive interim results from its Phase 2 clinical trial evaluating its darovaser more_horizontal

IDEAYA Biosciences, Inc.'s platform is synthetic lethality targeting cancer. The company has produced solid proof of concept data from multiple progra more_horizontal